Articles tagged with Immune Response
A new modeling study examines the impact of one versus two doses of a COVID-19 vaccine on infections and immune escape. The study finds that while one-dose strategies may reduce short-term infections, weak immunity could lead to long-term virus replication and mutation.
A Princeton University and McGill University study found that delaying second COVID-19 vaccine doses reduces case numbers in the short term. However, longer-term case burden and potential viral escape from immunity may depend on the strength and duration of immune responses generated by natural infections or one to two vaccine doses.
A study by Virginia Tech researchers reveals that a specific bacterium in mom's milk can educate an infant's antibody response, potentially strengthening their immune system. The findings suggest that probiotics could be used to protect infants from enteric infections and autoimmune diseases.
Researchers found that high levels of antibodies against a specific part of the virus may be key to understanding immune response to COVID-19. Individuals with stronger antibody responses showed immune functions associated with natural protection, offering a promising avenue for vaccine development and effective global rollout.
A recent study published in Eurosurveillance found that one dose of the Pfizer vaccine triggers a strong immune response in people who have previously been infected with SARS-CoV-2. The researchers also observed similar responses across multi-ethnic groups, suggesting that vaccination priority for those previously infected may not be n...
Researchers found a subpopulation of adults who don't sustain an antibody response after RSV reinfection, making them susceptible to reinfection. The 'original antigenic sin' phenomenon also emerged, where the immune system responds more to older infections than recent ones.
A new DNA-based vaccine platform has been shown to induce potent immune responses in mice, generating high levels of antibodies and strong T cell responses. The vaccine was found to be immunogenic, efficiently neutralizing the SARS-CoV-2 virus after a single immunization.
A new intranasal influenza vaccine demonstrated a durable immune response in a Phase 1 study, producing higher antibody levels compared to oral vaccination. The vaccine induced mucosal immunity and neutralizing antibodies at 26 weeks after vaccination, with sustained protection lasting up to five years.
A study by Hokkaido University reveals that tick saliva contains prostaglandin E2, which suppresses the immune response of helper T cells in cattle. This finding could lead to better protection for cattle against tick-borne diseases.
A recent study published in Cell Report Medicine has provided a detailed look at the vulnerable sites on the novel coronavirus SARS-CoV-2 that T cells can attack. The research found that T cells can recognize dozens of epitopes on the virus, including several additional sites on the spike protein.
Research suggests adult males are twice as likely to die from severe COVID-19 as females due to biological factors, according to a new Perspective article. Differences in antiviral immune responses between the sexes, including sex-specific genes and hormone roles, may underlie this male bias.
Researchers from RUDN University and RLT propose that stimulating lymphocyte regeneration with combined biophysical radiances can help fight COVID-19. They found a correlation between bioenergetics and immune system reactions, suggesting a potential solution to the disease's progression.
The study found new biomarkers related to changes in protein function involved in novel regulatory mechanisms of metabolic and immunological pathways in blue mussels, soft-shell clams, Eastern oysters, and Atlantic jackknife clams. Biomarker identification will benefit the aquaculture industry.
A recent study found that female COVID-19 patients experience less severe complications due to stronger immune responses triggered by their X chromosome-linked genes. Women's immune systems are enhanced by the presence of Toll-like receptor seven, allowing them to better tolerate virus infections.
A preliminary study found that a drug helping immune cells self-clean can improve vaccine protection in older adults. The drug boosts autophagy, which is blunted in older individuals, restoring immune cell function and enhancing vaccination efficiency.
A study published in Cell Reports identified a protein called SHP-1 as a key player in the Leishmania parasite's evasion of the human immune system. By activating SHP-1, the parasite can limit the capacity of dendritic cells to present antigens, thereby preventing autoimmune disorders and protecting itself from an immune response.
A new study suggests that targeting the RANK signaling pathway can enhance antitumor immune responses, making breast cancer more responsive to immunotherapy. The findings come from a clinical trial and preclinical research, demonstrating the potential of this approach to convert 'cold' tumors into 'warm' ones.
A computational method combining clinicodemographic variables and deep learning of pre-treatment histology images accurately predicts response to immune checkpoint blockade. The model, validated in an independent cohort, achieves high accuracy and can stratify patients into high versus low risk for disease progression.
A study published in Nature Medicine found that survivors of SARS-CoV-2 infection develop long-lasting immunity through memory T-cells, providing protection against re-infection. The research team's findings raise hopes for the development of effective vaccines.
A new study found that COVID-19 patients' early antibody evolution differs between survivors and non-survivors, with the former developing strong IgG antibodies and targeting the S2-domain on coronaviruses. This immunity may help patients generate killer antibodies faster and sooner after infection.
Researchers suggest that vitamin C therapy for COVID-19 may be effective in certain populations, but its success could be hindered by low levels of the natural transporter needed to get the vitamin inside cells. Factors such as age, race, and genetic variations of the transporter also impact effectiveness.
A new biomaterial-based cancer vaccine has shown promise in treating aggressive triple-negative breast cancer (TNBC) in mice, with 100% survival rate after a subsequent injection of cancer cells. The vaccine combines chemotherapy and immunotherapy to generate a sustained anti-cancer response.
Researchers aim to boost protection against severe flu infection in babies under 6 months with a new vaccine approach.
A Duke Health-led research team has identified a key marker that will help speed effective vaccine designs for cytomegalovirus (CMV). The finding provides an immune surrogate to test the effectiveness of vaccine candidates, which could aid in vaccine evaluation and predict potential efficacy.
Researchers found a subset of COVID-19 patients who cleared the disease quickly and sustained virus-specific antibody production, indicating a more effective immune response. These 'sustainers' had shorter symptoms and differences in memory T cell populations and B cells.
Researchers at University at Buffalo have discovered a method to convert a coronavirus protein into a nanoparticle, which could lead to more effective vaccines against COVID-19. High antibody levels were induced in laboratory mice and rabbits after immunization with the RBD particles.
Researchers found that females can clear asymptomatic malaria infections at a faster rate than males, which could inform epidemiologists and public health strategies. The study, published in eLife, suggests biological sex-based differences play a crucial role in the human response to malaria parasites.
The study found associations between specific single nucleotide polymorphisms (SNPs) and clinical features of follicular lymphoma, including tumor microenvironment composition. The researchers identified key immune-related genes associated with worse survival outcomes in patients treated with rituximab-containing regimens.
Researchers found that elkhorn coral has a consistent immune response to diseases, indicating it actively fights off disease. The study suggests corals may have tougher epithelia and symbiotic dinoflagellates that develop differences in gene expression over time.
Researchers from the University of Gothenburg found that COVID-19 patients with brain impairment had elevated immune activation markers, but no viral presence in cerebrospinal fluid. This suggests that the patient's immune response may be the underlying cause of neural damage.
Researchers found that one third of human liver NK cells can remember viruses and respond specifically to them, making them an interesting target for prophylactic use in the fight against infections. This subset of NK cells exhibits a unique gene expression profile and could be used for specific vaccination strategies.
A specific region of messenger RNAs plays a crucial role in brain cell function. The study reveals an unusual EXAR (EXon-Activated Rescue) mechanism that secures this process, using ELAV and FNE proteins to determine neuronal transcript signatures.
A systematic review found that the severity of infectious diseases peaks in school-age children, with young adults facing a higher risk of severe disease. The study analyzed data on 32 different infections and suggests 'immune aging' may start as early as young adulthood.
Cedars-Sinai will investigate the diversity and determinants of immune-inflammatory response to SARS-CoV-2 in a diverse population, highlighting ethnic and racial disparities in COVID-19 risk and severity. The five-year grant aims to advance knowledge of immunology and coronavirus in the US.
A new study found that protective antibodies against COVID-19 persist for four months in survivors of serious infections, making them a valuable tool for tracking the spread of the virus in communities. The study also identified key antibody responses to COVID-19 that are relatively short-lived, declining within two and a half months.
Researchers analyzed blood samples from 232 COVID-19 patients using VirScan to identify 800 sites of the virus that the immune system can recognize, known as epitopes. The team detected a range of antibody frequencies against various epitopes, with some recognized by 79% of COVID-19 patients.
A new study found that the PLCG2-P522R genetic variant protects against Alzheimer's disease by enhancing immune cell functions, including phagocytic activity and immune response. The results highlight the importance of targeting this pathway for future therapy development.
Researchers at HSE University have discovered microRNA molecules that can bind to coronavirus genomes, slowing down their replication and potentially allowing the virus to delay an active immune response. The study found four families of human miRNAs with binding sites for all seven types of human coronaviruses, including SARS-CoV-2.
Researchers discovered that parasitic and non-parasitic plants respond to quinones, a class of organic compounds. Non-parasitic plants produce a calcium signal in response to quinones, which triggers defensive responses against bacteria and other microbes.
Researchers found that UVB exposure expands regulatory T cells expressing proenkephalin and amphiregulin, promoting wound healing and keratinocyte growth. These PENK+UVB-skin Treg cells have a novel therapeutic potential for treating psoriasis and atopic dermatitis.
Researchers found that olfactory sensory neurons can activate antiviral genes to fight off the virus, but at a higher level than other cell types. This unique response may be a brain-protective mechanism, allowing these cells to avoid being destroyed by the infection.
Researchers at Georgia Institute of Technology developed a new microgel drug delivery method to improve pancreatic islet transplant success. The method uses an engineered biomaterial to deliver an immune-suppressing protein, reducing dosage and side effects.
The Cambridge-developed DNA vaccine candidate, DIOS-CoVax2, targets key regions of the virus to produce beneficial anti-viral responses. The vaccine aims to protect against SARS-CoV-2 and other related coronaviruses, with a potential for widespread use and low-cost manufacturing.
A team of researchers from the University of Melbourne has identified new mediators of immune exhaustion that may be targeted in therapies for cancer and severe viral infections. T cells can lose function within just a few days of severe infection, contrary to previous thought that it takes longer.
A study found that a bacteriophage infecting enterococcus bacteria stimulates an immune response improving the efficacy of cancer treatments. Administration of enterococcus containing the bacteriophage boosted T cell responses in mice, and its presence was associated with improved survival following PD-1 immunotherapy.
Researchers developed a test that shows transplant patients can form a good immune response to Sars-Cov-2, allowing for individualized adjustment of immunosuppression during Covid-19 infection. This is crucial for preventing severe infections in chronically ill patients with impaired immune defenses.
The study found that immune cells are produced in large quantities but their function is defective, leading to an ineffective immune response against the virus. In severe cases, immature cells with inhibitory effects on the immune response prevail.
Researchers found that anglerfishes with permanent attachments lack key immune molecules, leading to a severely blunted immune response. Instead, they rely on improved innate immune facilities to defend themselves against infections.
Scientists at Trinity College Dublin discovered a way to manipulate human immune responses to Mycobacterium tuberculosis, tipping the balance in favor of patients. The study used an epigenetic inhibitor to release pro-inflammatory signals that aid in clearing the infection, promoting future vaccine strategies.
A study published in PLOS Pathogens found that immunity to influenza accumulates during childhood and declines after 40-50 years of age. The researchers developed novel metrics to define key features of antibody profiles, which provide valuable tools for analyzing complex immune responses.
A study by Emory Vaccine Center found that adjuvants can strengthen both rookie and veteran elements of the immune response to a vaccine containing H5N1. This has significant implications for developing universal flu vaccines against multiple strains, as well as optimizing responses against SARS-CoV-2.
Researchers have developed a technology to obtain microvesicles from human stem cells, showing significant biological activity and therapeutic potential. The induced microvesicles can reduce the intensity of immune response and may be used to treat inflammations and autoimmune syndromes.
Researchers identified an enhanced immune response to the H5N1 influenza virus in a two-dose vaccination trial. The findings suggest that this approach could lead to the development of a universal flu vaccine targeting multiple strains.
A novel and extremely efficient synthesis method has been developed for bioactive natural compounds with potential anti-cancer properties. The new method allows easier access to these substances, enabling further investigations into their biological activity and potential therapeutic applications.
The current serotype of dengue virus in Singapore has the ability to transform its structure, evading the host's immune response and making vaccines and therapeutics less effective. This poses a significant challenge for developing effective treatments and preventing dengue infections.
A case series of five MS patients with favorable outcomes after developing COVID-19 while taking teriflunomide reveals potential benefits of the drug in preventing excessive immune responses. The study suggests that teriflunomide may not need to be discontinued in patients with MS who develop an active COVID-19 infection.
Scientists have found that baboons exhibit a steep age-related cognitive decline, similar to humans, making them a potentially useful model for testing early therapeutic interventions. The findings provide insight into the breakdown of brain systems and may lead to better treatments for Alzheimer's disease.
Researchers reprogrammed T-cells to recognize proteins as part of the body, preventing autoimmune diseases like multiple sclerosis. The study's findings have important implications for treating autoimmune conditions and may lead to advances in overcoming autoimmunity.
Researchers at Children's Hospital of Philadelphia have developed a strategy to identify regions of the SARS-CoV-2 virus to target with a vaccine, employing cancer immunotherapies. They prioritize viral targets based on their ability to stimulate a lasting immune response, predicted to be in the vast majority of the human population.
A research team from Genethon has successfully inhibited the immune response induced by AAV antibodies, paving the way for repeated administration of gene therapy treatments. This breakthrough could enable treatment of rare genetic diseases and improve patient outcomes.